Acura Pharmaceuticals Inc
OTC:ACUR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0001
0.02
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Acura Pharmaceuticals Inc
Operating Expenses
Acura Pharmaceuticals Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Acura Pharmaceuticals Inc
OTC:ACUR
|
Operating Expenses
-$2.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
12%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$37.9B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$19B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$28.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$26.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$22.9B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-8%
|
|
Acura Pharmaceuticals Inc
Glance View
Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.
See Also
What is Acura Pharmaceuticals Inc's Operating Expenses?
Operating Expenses
-2.8m
USD
Based on the financial report for Dec 31, 2021, Acura Pharmaceuticals Inc's Operating Expenses amounts to -2.8m USD.
What is Acura Pharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
12%
Over the last year, the Operating Expenses growth was 36%. The average annual Operating Expenses growth rates for Acura Pharmaceuticals Inc have been 14% over the past three years , 23% over the past five years , and 12% over the past ten years .